Stephen J. Hill - Nov 10, 2025 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role
Chief Operating Officer
Signature
/s/ Mark Meltz, Attorney-in-Fact
Stock symbol
LYEL
Transactions as of
Nov 10, 2025
Transactions value $
-$1,531
Form type
4
Date filed
11/12/2025, 08:31 PM
Previous filing
Oct 29, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Hill Stephen J. Chief Operating Officer C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SOUTH SAN FRANCISCO /s/ Mark Meltz, Attorney-in-Fact 2025-11-12 0001866154

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LYEL Common Stock Sale -$1.53K -95 -0.6% $16.12 15.8K Nov 10, 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.